Harmonizing Estradiol Reference Ranges in Postmenopausal Women: A Breakthrough for Accurate Hormone Assessment and Risk Prediction

Harmonizing Estradiol Reference Ranges in Postmenopausal Women: A Breakthrough for Accurate Hormone Assessment and Risk Prediction

This article reviews the establishment of international standardized reference ranges for plasma estradiol in postmenopausal women, highlighting the influence of BMI and assay harmonization using CDC standards, with implications for therapy monitoring and disease risk evaluation.
Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin

Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin

Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamicin. Allogeneic stem cell transplantation (allo-HSCT) benefits select high-risk patients.